Lilly's drug Zepbound showed superior weight loss compared to Wegovy in clinical trials.

From Nasdaq: 2025-05-11 21:46:00

Eli Lilly and Co. announced that their drug Zepbound (tirzepatide) showed superior weight reduction compared to Wegovy (semaglutide) in a Phase 3b clinical trial. Results from the SURMOUNT-5 trial were presented at the 32nd European Congress on Obesity and published in The New England Journal of Medicine. Participants on Zepbound lost an average of 20.2% of their weight compared to 13.7% on Wegovy at 72 weeks. Zepbound also outperformed Wegovy in key secondary endpoints, with a higher percentage of participants achieving significant weight loss and waist circumference reduction. Safety profile of Zepbound was consistent with previous trials.



Read more at Nasdaq: Lilly’s Zepbound Outperforms Wegovy In Phase 3b Trial For Weight Reduction